Catalent’s OptiForm Solution Suite Champions Contract Services and Outsourcing Category at the CPhI Pharma Awards

October 5, 2016
Pharmaceutical Technology Editors

The OptiForm Solution Suite platform offers easy, simple, fast, and cost-effective approaches for both small and macromolecules in early development phases.

The OptiForm Solution Suite and OptiForm Solution Suite Bio from Catalent Pharma Solutions emerged as the winner of the Contract Services and Outsourcing category at the CPhI Pharma Awards gala, held on Oct. 4, 2016 in Barcelona, Spain.

The OptiForm Solution Suite platform offers easy, simple, fast, and cost-effective approaches for both small and macromolecules in early development phases. It addresses bioavailability challenges of small molecules at an early phase of development. The platform is an integrated service using a unique toolkit of bioavailability enhancing technologies, including comprehensive molecule characterization and unique salt screening assessment, combined with parallel processing with four superior formulation technologies.

To expand the service to the early phase development of peptides and macromolecules, OptiForm Solution Suite Bio was launched to rapidly screen biomolecules’ potential for a non-invasive delivery route. It employs two advanced formulation technologies: OptiGel Bio and Zydis Bio technologies, utilizing a parallel screening model to deliver in-vivo study material in three weeks.

The number of poorly soluble molecules is increasing, causing many promising therapies to be delayed or even fail because of poor bioavailability. Although a few enabling technologies are available, there is no “one size fits all” approach to overcome bioavailability challenges. Early on in development, scientists need to rapidly identify the most suitable formulations that can provide the optimal treatment to patients. OptiForm Solution Suite and OptiForm Solution Suite Bio offer several advantages to drug developers:

Easier:  OptiForm Solution Suite and OptiForm Solution Suite Bio are integrated solutions requiring minimal material. The platform enables partners to rapidly progress development programs.

Simpler: The results are optimal recommendations, based on real data. Each customer project is assigned a dedicated scientific advisor who will thoroughly discuss the testing results and recommendations for a path to clinic.

Faster: OptiForm Solution Suite and OptiForm Solution Suite Bio employ accelerated parallel processes with superior formulation technologies. OptiForm Solution Suite delivers optimized animal pharmacokinetic material, with two week’s stability data, in 12 weeks and OptiForm Solution Suite Bio provides in-vivo study material in three weeks.

For developers, the platforms give access to expertise and a diverse range of technologies and screening techniques, so decisions can be made on real data. Feasibility studies can be carried out faster and earlier so as the risk of failure and reformulation delays in development can be minimized.